Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 244

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Vitamin Intervention for Stroke Prevention Trial: An Efficacy Analysis

Open access
Spence, J. David, Bang, Heejung, Chambless, Lloyd E., Stampfer, Meir J.·2005·Stroke

Abstract

Background and Purpose— The Vitamin Intervention for Stroke Prevention trial (VISP) intention-to-treat analysis did not show efficacy of combined vitamin therapy for recurrent vascular events in patients with nondisabling stroke. Reasons for lack of efficacy may have included folate fortification of grain products, inclusion of the recommended daily intake for B 12 in the low-dose arm, treatment with parenteral B 12 in patients with low B 12 levels in both study arms, a dose of B 12 too low for patients with malabsorption, supplementation with nonstudy vitamins, and failure of patients with significant renal impairment to respond to vitamin therapy. We conducted an efficacy analysis limited to patients most likely to benefit from the treatment, based on hypotheses arising from evidence developed since VISP was initiated. The criteria for this subgroup were defined before any data analysis. Methods— For this analysis, we excluded patients with low and very high B 12 levels at baseline (<250 and >637 pmol/L, representing the 25th and 95th percentiles), to exclude those likely to have B 12 malabsorption or to be taking B 12 supplements outside the study and patients with significant renal impairment (glomerular filtration rate <46.18; the 10th percentile). Results— This subgroup represents 2155 patients (37% female), with a mean age of 66±10.7 years. For the combined end point of ischemic stroke, coronary disease, or death, there was a 21% reduction in the risk of events in the high-dose group compared with the low-dose group (unadjusted P =0.049; adjusted for age, sex, blood pressure, smoking, and B 12 level P =0.056). In Kaplan–Meier survival analysis comparing 4 groups, patients with a baseline B 12 level at the median or higher randomized to high-dose vitamin had the best overall outcome, and those with B 12 less than the median assigned to low-dose vitamin had the worst ( P =0.02 for combined stroke, death, and coronary events; P =0.03 for stroke and coronary events). Conclusions— In the era of folate fortification, B 12 plays a key role in vitamin therapy for total homocysteine. Higher doses of B 12 , and other treatments to lower total homocysteine may be needed for some patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.str.0000185929.38534.f3

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 244

Metadata

Authors
Spence, J. D., Bang, H., Chambless, L. E., & Stampfer, M. J.
Venue
Stroke
Published
2005-11
Volume
36
Issue
11
Pages
2404-2409
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
OpenAlex
W2169022408
Cited by
244
References
2
FWCI
14.27
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vitamin Intervention for Stroke Prevention Trial: An Efficacy Analysis. https://app.cochat.ai/papers/10.1161/01.str.0000185929.38534.f3
The paper
Spence, J. D., Bang, H., Chambless, L. E., & Stampfer, M. J. (2005). Vitamin Intervention for Stroke Prevention Trial: An Efficacy Analysis. Stroke. https://doi.org/10.1161/01.str.0000185929.38534.f3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.